MYIA
ATOS icon

Mount Yale Investment Advisors’s Atossa Therapeutics ATOS Stock Holding History

Mount Yale Investment Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33
Closed -$415 – 742
2025
Q2 		$415 Buy
+33
New +$395 ﹤0.01% 1423

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mount Yale Investment Advisors's ATOS Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 33 shares — an estimated $415 sold.

Mount Yale Investment Advisors first reported a position in ATOS in Q2 2025 and held it in 1 quarter. The position peaked at $415 in Q2 2025. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 33 Atossa Therapeutics shares in Q3 2025, an estimated $415.
  • Mount Yale Investment Advisors first reported a position in Atossa Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mount Yale Investment Advisors's Atossa Therapeutics position peaked at $415 in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.